Conduit Expands Autoimmune Pipeline With New Patents For CDT1656

Conduit Pharmaceuticals Inc. announced it has filed two new patent applications covering its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca. This is aimed at being applied in treating various autoimmune diseases. One of the applications is a novel composition of matter introducing CDT1656, a combination of AZD1656 and another compound that affects the advancement of autoimmune diseases. 

This addition will expand Conduit's pipeline with innovative therapies for multiple autoimmune conditions, positioning the company to reach a broader patient population. Conduit believes CDT1656 can expand its market reach across diverse autoimmune conditions, thus improving its strategic portfolio.

These filings exhibit Conduit's dedication to expanding its IP portfolio, with specific emphasis placed on developing products that could be combined with marketed treatments to enhance patient responses. The strategy will involve the further development of IPs to increase the licensing potential and, at the same time, strategic capture of market shares through targeting products that have patents coming up or have known vulnerabilities in IP. Its portfolio will, therefore, remain competitive and commercially viable.

The autoimmune disease therapeutics market, which is valued at approximately $214.54 billion in 2024, is projected to expand at a compound annual growth rate of 7.9%, potentially reaching $339 billion by 2030. With its promising profile, CDT1656 stands to open new market opportunities, broadening therapeutic choices and strengthening the growth prospects of the company’s in this rapidly advancing field. 

Dr. David Tapolczay, Chief Executive Officer at Conduit, said, "The filing of these two new patents reflects our dedication at Conduit to maximizing our IP portfolio and highlights the strength of research and development at our Cambridge, UK laboratory. By securing exclusive rights to CDT1656, a combination of AZD1656 and a second compound which offers additional autoimmune benefits, we are positioning Conduit for future licensing opportunities and market growth. These developments demonstrate our commitment to driving value through strategic IP creation and capitalizing on untapped opportunities in the sector."